Only an overall 15% net benefit emerges in favour of adjuvant intravesical chemotherapy when compared to transurethral resection alone for the prevention of recurrences of superficial bladder tumors.
Colombo
Renzo
R
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D006801:Humans; D010535:Laparoscopy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000970:Antineoplastic Agents